Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression

International Clinical Psychopharmacology

Volumn 17, Issue 2, 2002, Pages 45-51

  Ferguson, James M ^a   Mendels, J ^a   Schwartz, G E ^a  

^a Pharmacol R Clin Protoc Tri 448   (United States)

Author keywords

HAM D factors; Major depression; Norepinephrine reuptake inhibitor; Reboxetine; Selective NRI

Indexed keywords

NORADRENALIN UPTAKE INHIBITOR; PLACEBO; REBOXETINE;

ADULT; ARTICLE; CLINICAL TRIAL; COGNITION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SWEATING; TREATMENT OUTCOME; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0036186943     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200203000-00001     Document Type: Article

References (20)

1. Clinical efficacy of reboxetine: A comparative study with desipramine, with methodological considerations
2. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes
3. Depressed in-patients respond differently to imipramine and mirtazapine
4. Noradrenaline-selective versus serotonin-selective antidepressant therapy: Differential effects on social functioning
5. A rating scale for depression
6. Effect of antidepressants on cognitive and psychomotor function: Lack of effect of reboxetine
7. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorder: A double-blind randomised trial
8. Reboxetine: A double-blind comparison with fluoxetine in major depressive disorder
9. Double-blind, multicenter comparative study of sertraline and amitriptyline in hospitalized patients with major depression
10. Is there a role for a pure noradrenergic drug in the treatment of depression?
11. Role of norepinephrine in the pathophysiology and treatment of mood disorders
12. Effects of reboxetine on anxiety, agitation and insomnia
13. Antidepressant treatment of the depressed patient with insomnia
14. Comorbid anxious signs and symptoms in major depression: Impact on functional work capacity and comparative treatment outcomes
15. The link between sleep and depression: The effects of antidepressants on EEG sleep
16. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder
17. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder